Legal status by country
Is Tirzepatide with BPC-157 legal?
Written by Aaron CuhaReviewed Sep 2026
How Tirzepatide with BPC-157 is classified in the United States, United Kingdom, Australia and Canada, side by side. Each country has its own page with a direct answer, the regulator's approval status and what the classification means in practice.
All four countries, side by side
| Attribute | United States · FDA | United Kingdom · MHRA | Australia · TGA | Canada · Health Canada |
|---|---|---|---|---|
| Status | Not approved | Not approved | Not approved | Not approved |
| Classification | Not approved; research use only | Not licensed | Not approved | Not approved |
| Note | Tirzepatide is FDA approved; BPC-157 is not approved and cannot lawfully be compounded, so any premixed product is unlawful on the second ingredient. | Tirzepatide is licensed; BPC-157 is an unlicensed medicine and supply for human use is unlawful. | None recorded | None recorded |
US FDA status: Tirzepatide is approved. BPC-157 is not approved, was reviewed by FDA staff in July 2026 with no adequate human data found, and is not a permitted compounding ingredient. The combination has never been evaluated.. Reviewed Sep 2026.
Related compounds
General information current as of Sep 2026, not legal advice. Classifications change; confirm with the regulator or a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships.